Novel functions of phospholipases
Novel functions of phospholipases
批准号:
10212202
负责人:
INOUE Keizo
金额:
$62.59万
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research on Priority Areas (B)
财政年份:
1998
资助国家:
日本
项目状态:
已结题
起止时间:
1998 至 2001
中文摘要
三个新的磷脂酶的生理作用进行了分析,通过生产敲除动物。磷脂酶是I型血小板活化因子乙酰水解酶(PAF-AH(I))、II型血小板活化因子乙酰水解酶(PAF-AH(II))和磷脂酰丝氨酸特异性磷脂酶A1(PS-PLA 1)。对于PAF-AH(I)和PS-PLA 1,我们已经制造了敲除小鼠,对于PAF-AH(II),我们已经制造了敲除秀丽隐杆线虫,因为生物体表达PAF-AH(II)的哺乳动物同源物。表:基因敲除动物的表型动物表型PAF-AH(I)小鼠精子形成异常PAF-AH(II)秀丽隐杆线虫表皮形成异常PS-PLA 1小鼠T细胞发育异常由于这些表型不是预期的,因此建议每种磷脂酶具有新的功能,这些功能应在进一步的研究中解决。
英文摘要
Physiological roles of three novel phospholipases have been analysed by producing knockout animals. The phospholipases are type I platelet-activating factor acetylhydrolase (PAF-AH (I)), type II platelet-activating factor acetylhydrolase (PAF-AH (II)), and phosphatidylserine-specific phospholipase A1 (PS-PLA1). For PAF-AH (I) and PS-PLA1, we have made knock out mice, and for PAF-AH (II), we have made knockout C.elegans, as the organism express mammalian homologue of PAF-AH (II). The phenotype of each animal are shown in table ;Table : Phenotype of knockout animalsanimals phenotypePAF-AH (I) mice abnormality on sperm formationPAF-AH (II) c.elegans abnormality in epidermis formationPS-PLA1 mice abnormality in T cell developmentAs these phenotype are not expected, novel function for each phospholipase is suggested, which should be solved in further studies.
期刊论文(30)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
Nagai, Y. et al.: "An alternative splicing form of phosphatidylserine-specific phospholipase A1 that exhibits lysophosphatidylserine-specific lysophospholipase activity in humans"J. Biol. Chem.. 274. 11053-11059 (1999)
Nagai, Y. 等人:“磷脂酰丝氨酸特异性磷脂酶 A1 的另一种剪接形式,在人类中表现出溶血磷脂酰丝氨酸特异性溶血磷脂酶活性”J.
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
K.Hayashi et al.: "Phenotypic Modulation of vascular smooth muscle cells induced by unsaturated lysophosphatidic acids"Circulation Res.. 89. 251-258 (2001)
K.Hayashi 等人:“不饱和溶血磷脂酸诱导的血管平滑肌细胞的表型调节”循环研究 89. 251-258 (2001)
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
Erickson J.R., et al.: "Lysophosphatidic acid and ovarian cancer : a paradigm for tumorogenesis and patient management"Prostaglandins Other Lipid Mediat. 64. 63-81 (2001)
Erickson J.R. 等人:“溶血磷脂酸和卵巢癌:肿瘤发生和患者管理的范例”前列腺素其他脂质介质。
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
Bandoh,K.et al.: "Lysophosphatidic acid (LPA) receptors of the EDG family are differentially activated by LPA species-Structure-activity relationship of cloned LPA receptors-"FEBS letter. 478. 159-165 (2001)
Bandoh,K.等人:“EDG 家族的溶血磷脂酸 (LPA) 受体被 LPA 种类不同地激活 - 克隆 LPA 受体的结构-活性关系 -”FEBS 信。
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
共 23 条
Patho-Physiological function of Phosphatidylserine-specific Phospholipase A1-Specific role of PS-PLA 1 in mast cell activation-
-
批准号:10557218
-
项目类别:Grant-in-Aid for Scientific Research (B).
-
资助金额:$8.51万
-
财政年份:1998
-
负责人:INOUE Keizo
-
依托单位:
NEW FUNCTION OF PHOSPHOLIPASE A
-
批准号:08407071
-
项目类别:Grant-in-Aid for Scientific Research (A)
-
资助金额:$21.44万
-
财政年份:1996
-
负责人:INOUE Keizo
-
依托单位:
Basic study for analysis and application of bio-factor which regulate transfer of cholresterol in vivo.
-
批准号:06557128
-
项目类别:Grant-in-Aid for Scientific Research (A)
-
资助金额:$9.09万
-
财政年份:1994
-
负责人:INOUE Keizo
-
依托单位:
Biological functions of mammalian non-pacreatic type Phospholipase A_2
-
批准号:04404081
-
项目类别:Grant-in-Aid for General Scientific Research (A)
-
资助金额:$11.2万
-
财政年份:1992
-
负责人:INOUE Keizo
-
依托单位:
Biochemical Studies on Platelet Phospholipase A_2
-
批准号:63480490
-
项目类别:Grant-in-Aid for General Scientific Research (B)
-
资助金额:$4.03万
-
财政年份:1988
-
负责人:INOUE Keizo
-
依托单位:
Effective Production of Monoclonal Antibodies Against Low Immunogenic Substances
-
批准号:63870013
-
项目类别:Grant-in-Aid for Developmental Scientific Research (B).
-
资助金额:$4.54万
-
财政年份:1988
-
负责人:INOUE Keizo
-
依托单位:
Construction and application of cloning vector which carries signal sequence of Escherichia coli.
-
批准号:60880018
-
项目类别:Grant-in-Aid for Developmental Scientific Research
-
资助金额:$18.82万
-
财政年份:1985
-
负责人:INOUE Keizo
-
依托单位:
海外基金